Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion

References

• Benita S, Levy MY. (1993). Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J Pharm Sci, 82(11): 1069–1079.
   PubMed Web of Science ®Google Scholar
• Collins-Gold LC, Lyons RT, Bartholow LC. (1990). Parenteral emulsions for drug delivery. Adv Drug Deliv Rev, 5(3): 189–208.
   Google Scholar
• Desai A, Vyas T, Amiji M. (2008). Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci, 97(7): 2745–2756.
   PubMed Web of Science ®Google Scholar
• Dorr R, Fritz W. (1982). Cancer Chemotherapy Handbook. New York: Elsevier Science.
   Google Scholar
• Driscoll DF. (2006). Lipid injectable emulsions: 2006. Nutr Clin Pract, 21(4): 381–386.
   PubMedGoogle Scholar
• Francis GE, Delgado C, Fisher D, Malik F, Agrawal AK. (1996). Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J Drug Target, 3(5): 321–340.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. (1997). Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev, 24(2-3): 337–344.
   Web of Science ®Google Scholar
• Galton D, Israels L, Nabarro J, Till M. (1965). Clinical trials of p.di (2-chloroethylamine)-phenylbutyric acid (CB1348) in malignant lymphoma. BMJ, II: 1172.
   Google Scholar
• Ganta S, Amiji M. (2009). Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm, 6(3): 928–939.
   PubMed Web of Science ®Google Scholar
• Ganta S, Devalapally H, Baguley BC, Garg S, Amiji M. (2008a). Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells. J Biomed Nanotechnol, 4: 165–173.
   Web of Science ®Google Scholar
• Ganta S, Paxton JW, Baguley BC, Garg S. (2008b). Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm, 360(1-2): 115–121.
   PubMed Web of Science ®Google Scholar
• Hall AG, Tilby MJ. (1992). Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev, 6(3): 163–173.
   PubMed Web of Science ®Google Scholar
• Handa T, Saito H, Miyajima K. (1990). Phospholipid monolayers at the triolein-saline interface: production of microemulsion particles and conversion of monolayers to bilayers. Biochemistry, 29(11): 2884–2890.
   PubMed Web of Science ®Google Scholar
• Hultin M, Carneheim C, Rosenqvist K, Olivecrona T. (1995). Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res, 36: 2174–2184.
   PubMed Web of Science ®Google Scholar
• Igarashi R, Takenaga M, Matsuda T. (1996). Distribution of lipid microsphere preparations. Adv Drug Deliv Rev, 20(2-3): 147–154.
   Web of Science ®Google Scholar
• Jain RK. (1994). Barriers to drug delivery in solid tumors. Sci Am, 271(1): 58–65.
   PubMed Web of Science ®Google Scholar
• Khandavilli S, Panchagnula R. (2007). Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Invest Dermatol, 127: 154–162.
   PubMed Web of Science ®Google Scholar
• Lundberg BB, Mortimer BC, Redgrave TG. (1996). Submicron lipid emulsions containing amphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time. Int J Pharm, 134(1-2): 119–127.
   Web of Science ®Google Scholar
• Lundberg BB, Griffiths G, Hansen HJ. (1999). Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions. J Pharm Pharmacol, 51: 1099–1105.
   PubMed Web of Science ®Google Scholar
• Maeda H, Matsumura Y. (1989). Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst, 6: 193–210.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65(1–2): 271–284.
   PubMed Web of Science ®Google Scholar
• Mizushima Y, Hoshi K. (1993). Recent advances in lipid microspheres technology for targeting prostaglandin delivery. J Drug Target, 1: 93–100.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53(2): 283–318.
   PubMed Web of Science ®Google Scholar
• Oku N, Namba Y. (1994). Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst, 11: 231–270.
   PubMed Web of Science ®Google Scholar
• Ozono S, Miyao N, Igarashi T, Marumo K, Nakazawa H, Fukuda M, Tsushima T, Tokuda N, Kawamura J, Murai M. (2004). Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn J Clin Oncol, 34(2): 82–85.
   PubMed Web of Science ®Google Scholar
• Patlolla RR, Vobalaboina V. (2005a). Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. J Drug Target, 13(10): 543–553.
   PubMed Web of Science ®Google Scholar
• Patlolla RR, Vobalaboina V. (2005b). Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. J Pharm Sci, 94(2): 437–445.
   PubMed Web of Science ®Google Scholar
• Rossi J, Giasson S, Khalid MN, Delmas P, Allen C, Leroux J-C. (2007). Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors. Eur J Pharm Biopharm, 67(2): 329–338.
   PubMed Web of Science ®Google Scholar
• Sarker DK. (2005). Engineering of nanoemulsions for drug delivery. Curr Drug Deliv, 2: 297–310.
   PubMedGoogle Scholar
• Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T. (2004). A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int J Pharm, 273(1–2): 75–83.
   PubMed Web of Science ®Google Scholar
• Shimada K, Miyagishima A, Sadzuka Y, Nozawa Y, Mochizuki Y, Ohshima H, Hirota S. (1995). Determination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomes. J Drug Target, 3(4): 283–289.
   PubMed Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev, 17(1): 31–48.
   Web of Science ®Google Scholar